NCT07860359Not yet recruiting
Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers
Smoking Termination Outcomes With Pulmonary Low Dose Computed Tomography for Lung Cancer Screening (STOP-LungCancer)
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
Lung cancer is common and serious, but when detected early, the chances of recovery are significantly better. Tobacco use is the leading cause. To help people break free from smoking, the Fribourg Cantonal Hospital (HFR), the Center for Tobacco Prevention (CIPRET), and the Fribourg Cancer League are joining forces in the STOP-LungCancer study (Smoking Termination Outcomes with Pulmonary Low Dose Computed Tomography for Lung Cancer Screening). What is the goal of this study? The investigators want to determine whether seeing and understanding images of the participants' own lungs helps participants quit smoking for good. Smoking cessation will be verified at 6 months using a breath test (measuring carbon monoxide), followed by a 2-year follow-up. How does participation work? The study is open to 116 residents of the canton of Fribourg aged 50 to 79 who are heavy smokers and motivated to quit. The program includes: 1. Personalized support: 4 smoking cessation coaching sessions organized by CIPRET. 2. Lung computed tomography (CT) scans: 3 exams spaced one year apart. This scan involves no needles or injections. The radiation dose is very low, about 0.6 millisieverts (mSv) per scan, and the associated risk is considered very low. 3. A review of the images with a doctor: During dedicated consultations, a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain the condition of the lungs and heart. What are the benefits? Participants receive both tailored support to quit smoking and close monitoring to detect any potential issues at a very early stage.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- First submitted
- 30 Sept 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 30 Jun 2031
- Lead sponsor
- Hôpital Fribourgeois
- Diseases
- Lung cancer
- NCT number
- NCT07860359
What you commit to
- Study type: Interventional
- Planned participants: 116
- From 1 Jan 2027 to the primary completion date, 30 Jun 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of cancer
Other
- Major medical problems (Eastern Cooperative Oncology Group, ECOG ≥ 2)
- Chest computed tomography (CT) scan in the last 12 months
- Hemoptysis or unintentional weight loss \> 7 kilograms (kg) in the last year
- Pregnancy
- Refusal to be informed of incidental findings of medical importance
Who the study is looking for
- Residence in the canton of Fribourg
- Willingness to quit smoking
- Current smoker: \> or = 20 packs years
Age in the registry: 50 years to 79 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fribourg Cantonal Hospital (HFR) Coordinator of this site? Confirm its status | Fribourg | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.